Free Trial
NASDAQ:MLTX

MoonLake Immunotherapeutics Q4 2024 Earnings Report

MoonLake Immunotherapeutics logo
$43.50 +0.50 (+1.16%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$43.50 +0.01 (+0.01%)
As of 06/18/2025 06:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MoonLake Immunotherapeutics EPS Results

Actual EPS
-$0.72
Consensus EPS
-$0.63
Beat/Miss
Missed by -$0.09
One Year Ago EPS
N/A

MoonLake Immunotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MoonLake Immunotherapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Wednesday, February 26, 2025
Conference Call Time
9:30AM ET

Upcoming Earnings

MoonLake Immunotherapeutics' Q1 2025 earnings is scheduled for Wednesday, August 6, 2025

MoonLake Immunotherapeutics Earnings Headlines

Cantor Fitzgerald Weighs in on MLTX FY2026 Earnings
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
See More MoonLake Immunotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MoonLake Immunotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MoonLake Immunotherapeutics and other key companies, straight to your email.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics (NASDAQ:MLTX), a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

View MoonLake Immunotherapeutics Profile

More Earnings Resources from MarketBeat